يعرض 1 - 17 نتائج من 17 نتيجة بحث عن '"оценка стабильности"', وقت الاستعلام: 0.45s تنقيح النتائج
  1. 1
    Academic Journal
  2. 2
    Conference

    المؤلفون: Непомнящий, А. С.

    المساهمون: Гордынец, Антон Сергеевич

    وصف الملف: application/pdf

    Relation: Перспективные материалы конструкционного и функционального назначения : сборник научных трудов Международной научно-технической молодежной конференции, Томск, 17–21 октября 2022 г.; Непомнящий, А. С. Оценка стабильности дуговой сварки покрытыми электродами / А. С. Непомнящий; науч. рук. А. С. Гордынец // Перспективные материалы конструкционного и функционального назначения : сборник научных трудов Международной научно-технической молодежной конференции, Томск, 17–21 октября 2022 г. — Томск : Изд-во ТПУ, 2022. — [С. 66-68].; http://earchive.tpu.ru/handle/11683/74198

  3. 3
    Academic Journal
  4. 4
    Academic Journal

    وصف الملف: application/pdf

    Relation: Драч, А. А. Оценка стабильности бензина / А. А. Драч, С. А. Бурый // Наука - шаг в будущее : тезисы докладов XVI студенческой научно-практической конференции факультета технологии органических веществ, Минск, 30 ноября - 1 декабря 2022 г. - Минск : БГТУ, 2022. – С. 22.; https://elib.belstu.by/handle/123456789/53999; 662.75

  5. 5
    Academic Journal

    المساهمون: The study reported in this publication was carried out as part of a publicly funded research project No. 056-00023-18-02 and was supported by the Scientific Centre for Expert Evaluation of Medicinal Products (R&D public accounting No. AAAA-A18-118021590046-9)., Работа выполнена в рамках государственного задания ФГБУ «НЦЭСМП» Минздрава России № 056-00023-18-02 на проведение прикладных научных исследований (номер государственного учета НИР AAAA-A18-118021590046-9)

    المصدر: Biological Products. Prevention, Diagnosis, Treatment; Том 18, № 4 (2018); 243-248 ; БИОпрепараты. Профилактика, диагностика, лечение; Том 18, № 4 (2018); 243-248 ; 2619-1156 ; 2221-996X ; 10.30895/2221-996X-2018-18-4

    وصف الملف: application/pdf

    Relation: https://www.biopreparations.ru/jour/article/view/196/153; Terranella A, Asay GR, Messonnier ML, Clark TA, Liang JL. Pregnancy dose Tdap and postpartum cocooning to prevent infant pertussis: a decision analysis. Pediatrics. 2013;131(6):1748–56. https://doi.org/10.1542/peds.2012-3144; Cortese MM, Baughman AL, Zhang R, Srivastava PU, Wallace GS. Pertussis hospitalizations among infants in the United States, 1993 to 2004. Pediatrics. 2008;121(3):484–92. https://doi.org/10.1542/peds.2007-1393; Gustafsson L, Hallander HO, Olin P, Reizenstein E, Storsaeter J. A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. N Engl J Med. 1996;334(6):349–55. https://doi.org/10.1056/NEJM199602083340602; Winter K, Harriman K, Zipprich J, Schechter R, Talarico J, Watt J, Chavez G. California pertussis epidemic, 2010. J Pediatr. 2012;161(6):1091–6. https://doi.org/10.1016/j.jpeds.2012.05.041; Choi YH, Campbell H, Amirthalingam G, van Hoek AJ, Miller E. Investigating the pertussis resurgence in England and Wales, and options for future control. BMC Med. 2016;14(1):121. https://doi.org/10.1186/s12916-016-0665-8; Gambhir M, Clark TA, Cauchemez S, Tartof SY, Swerdlow DL, Ferguson NM. A change in vaccine efficacy and duration of protection explains recent rises in pertussis incidence in the United States. PLoS Comput Biol. 2015;11(4):e1004138. https://doi.org/10.1371/journal.pcbi.1004138; Clark TA. Changing pertussis epidemiology: everything old is new again. J Infect Dis. 2014;209(7):978–81. https://doi. org/10.1093/infdis/jiu001; Wendelboe AM, Van Rie A, Salmaso S, Englund JA. Duration of immunity against pertussis after natural infection or vaccination. Pediatr Infect Dis J. 2005;24(5):S58–61. https://www.doi.org/10.1097/01.inf.0000160914.59160.41; Shewhart W. Statistical method from the viewpoint of quality control. N.Y.: Dover Publ., Inc.; 1939; https://www.biopreparations.ru/jour/article/view/196

  6. 6
    Academic Journal

    المصدر: Biological Products. Prevention, Diagnosis, Treatment; № 1 (2015); 4-14 ; БИОпрепараты. Профилактика, диагностика, лечение; № 1 (2015); 4-14 ; 2619-1156 ; 2221-996X ; undefined

    وصف الملف: application/pdf

    Relation: https://www.biopreparations.ru/jour/article/view/2/3; Ярилин А.А. Иммунология. М.: ГЭОТАР-Медиа; 2010.; Медуницын Н.В. Вакцинология. М.: Триада-Х; 2010.; Кетлинский С.А., Симбирцев А.С. Цитокины. СПб: Фолиант; 2008.; Ковальчук Л.В., Ганковская Л.В., Мешкова Р.Я. Клиническая иммунология и аллергология с основами общей иммунологии. М.: ГЭОТАР-Медиа; 2012.; The Cytokine Handbook V. 1, 4th Edition, ed. A.W. Thomson, London: Elsevier Science Ltd; 2003.; Querol S., Cancelas J.A., Amat L., Capmany G., Garcia J. Effect of glycosylation of recombinant human granulocytic colony-stimulating factor on expansion cultures of umbilical cord blood CD34+ cells. Haematologica 1999; 84: 493-8.; Nohynek G.J., Plard J.P., Wells M.Y., Zerial A. Comparison of the potency of glycosylated and nonglycosylated recombinant human granulocyte colony-stimulating factors in neutropenic and nonneutropenic CD rats. Cancer Chemother Pharmacol. 1997; 39: 259-66.; Kubota N., Orita T., Hattori К, Oh-eda M., Ochi N., Yamazaki T. Structural characterization of natural and recombinant human granulocyte colony-stimulating factors. J Biochem. 1990; 107: 486-92.; Nissen С. Glycosylation of recombinant human granulocyte colony-stimulating factor: implications for stability and potency. Eur J Cancer. 1994; 30A(3): 12-4.; Oh-eda M., Hasegawa M., Hattori К., Kuboniwa H., Kojima T., Orita T., et al. O-linked sugar chain of human granulocyte colony-stimulating factor protects it against polymerization and denaturation allowing it to retain its biological activity. J Biol Chem. 1990; 265: 11432-5.; Ono M. Physicochemical and biochemical characteristics of glycosylated recombinant human granulocyte colony-stimulating factor (lenograstim). Eur J Cancer 1994; 30A(3): 7-11.; Wang С., Eufemi M., Turano C., Giartosio A. Influence of the carbohydrate moiety on the stability of glycoproteins. Biochemistry 1996; 35: 7299-307.; Arakawa T., Prestrelski S.J., Narhi L.O., Boone T.C., Kenney W.C. Cysteine 17 of recombinant human granulocyte-colony stimulating factor is partially solvent-exposed. J Protein Chem. 1993; 12: 525-31.; Lu H.S., Fausset P., Narhi L., Horan T., Shinagawa K., Shimamoto G., Boone T. Chemical modification and site-directed mutagenesis of methionine residues in recombinant human granulocyte colony-stimulating factor. Effect on stability and biological activity. Arch Biochem Biophys. 1999; 362(1): 1-11.; Akizuki S., Mizorogi F., Inoue T., Sudo K., Ohnishi A. Pharmacokinetics and adverse events following 5-day repeated administration of lenograstim, a recombinant human granulocyte colony-stimulating factor, in healthy subjects. Bone Marrow Transplant. 2000; 26: 939-46.; Pedrazzoli P., Gibelli N., Pavesi L., Preti P., Piolini M., Bertolini F., et al. Effects of glycosylated andnon-glycosylated G-CSFs, alone and in combination with other cytokines, on the growth of human progenitor cells. Anticancer Res. 1996; 16(4А): 1781-5.; Welte К., Gabrilove J., Bronchud M.H., Platzer E., Morstyn G. Filgrastim (r-metHuG-CSF): the first 10 years. Blood. 1996; 88: 1907-29.; Welte К., Reiter A., Mempel К., Pfetsch M., Schwab G., Schrappe M., Riehm H. A randomized phase-Ill study of the efficacy of granulocyte colony-stimulating factor in children with high-risk acute lymphoblastic leukemia. Blood 1996; 87: 3143-50.; Gisselbrecht G., Prentice H.G., Bacigalupo A., Biron P., Milpied N., Rubie H., et al. Placebo-controlled phase III trial of lenograstim in bone-marrow transplantation. Lancet. 1994; 343: 696-700.; Seymour A.M., de Campos E., Thatcher N., De Greve J., Cunningham D., Howell A., et al. A single-blind, randomised, vehicle-controlled dose-finding study of recombinant human granulocyte colony-stimulating factor (lenograstim) in patients undergoing chemotherapy for solid cancers and lymphoma. Eur J Cancer. 1995; 31A: 2157-63.; Höglund M., Smedmyr B., Bengtsson M., Tötterman TH., Cour-Chabernaud V., Yver A., Simonsson B. Mobilization of CD34+ cells by glycosyla ted and nonglycosylated G-CSF in healthy volunteers - a comparative study. Eur J Haematol. 1997; 59: 177-83.; Kim I.H., Park S.K., Suh O.K., Oh J.M. Comparison of lenograstim and filgrastim on haematological effects after autologous peripheral blood stem cell transplantation with high-dose chemotherapy. Curr Med Res Opin. 2003; 19(8): 753-9.; Watts M.J., Addison I., Long S.G., Hartley S., Warrington S., Boyce M., Linch D.C. Crossover study of the haematological effects and pharmacokinetics of glycosylated and non-glycosylated G-CSF in healthy volunteers. Br J Haematol. 1997; 98(2): 474-9.; Young D., Zhan H., Cheng Q., Hou J., Matthews D. Characterization of the receptor binding determinants of granulocyte colony stimulating factor. Protein Sci. 1997; 6(6): 1228-36.; Martino M., Console G., Irrera G., Callea I., Condemi A., Dattola A., et al. Harvesting peripheral blood progenitor cells from healthy donors: retrospective comparison of filgrastim and lenograstim. J Clin Apher. 2005; 20(3): 129-36.; Teramura M., Kimura A., Iwase S., Yonemura Y., Nakao S., Urabe A., et al. Treatment of severe aplastic anemia with antithymocyte globulin and cyclosporin A with or without G-CSF in adults: a multicenter randomized study in Japan. Blood 2007; 110(6): 1756-61.; Cooper K.L., Madan J., Whyte S., Stevenson M.D., Akehurst R.L. Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: systematic review and meta-analysis. BMC Cancer. 2011; 11: 404.; Aapro M.S., Bohlius J., Cameron D.A., Dal Lago L., Donnelly J.P., Kearney N., et al. 2010 update of EORTC guidelines for the use of granulocyte-colonystimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer. 2011; 47: 8-32.; Aapro M.S., Cameron D.A., Pettengell R., Bohlius J., Crawford J., Ellis M., et al. EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. Eur J Cancer. 2006; 42: 2433-53.; Clark O.A.C., Lyman G., Castro A.A., et al. Colony stimulating factors for chemotherapy induced febrile neutropenia. [Review]. Cochrane Database of Systematic Reviews. The Cochrane Collaboration. Published by John Wiley & Sons; 2008.; Johnston E., Crawford J., Blackwell S., Bjurstrom T., Lockbaum P., Roskos L., et al. Randomized, dose-escalation study of SD/01 compared with daily filgrastim in patients receiving chemotherapy. J Clin Oncol. 2000; 18(13): 2522-8.; Миронов А.Н., ред. Руководство по проведению доклинических исследований лекарственных средств (иммунобиологические лекарственные препараты). Ч. 2. М.: Гриф и К; 2012.; Миронов А.Н., ред. Руководство по экспертизе лекарственных средств. Т. М.: Гриф и К; 2013.; Guidelines on the quality, safety, and efficacy of biotherapeutic protein products prepared by recombinant DNA technology, 2013. Replacement of Annex 3 of WHO Technical Report Series, № 814. WHO Expert Committee on biological Standardization.; ICH S6 Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals. International Conference on Harmonisation; 1997.; ICH guideline S6 (R1) Preclinical safety evaluation of biotechnology-derived pharmaceuticals. EMA/CHMP/ICH/731268/1998.; ICH Q5D Derivation and Characterization of Cell Substrates Used for Production of Biotechnological/Biological Products. International Conference on Harmonisation; 1997.; ICH Q5A Viral Safety Evaluation of Biotechnology Products Derived from Cell Lines of Human or Animal Origin. International Conference on Harmonisation; 1997.; Европейская Фармакопея 7.0 (07/2010: 2206). Филграстим, раствор концентрированный. 2010; 4037-40.; ICH Q5С Quality of Biotechnological Products: Stability Testing of Biotechnological/Biological Products. International Conference on Harmonisation; 1995.; ICH Q1A (R2) Stability Testing of New Drug Substances and Products. International Conference on Harmonisation; 2003.; Similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues. EMEA/CHMP/BMWP/42832/2005.; Similar biological medicinal products containing biotechnology-derived proteins as active substance: quality issues. EMEA/CHMP/BMWP/49348/2005.; Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: quality issues (revision 1) EMEA/CHMP/BWP/247713/2012. London. 2014.; Guideline on similar medicinal products containing recombinant granulocyte-colony stimulating factor. EMEA/CHMP/BMWP/31329/2005.; ICH Q2A Validation of Analytical Procedures. International Conference on Harmonisation; 1994.; ICH Q2B Validation of Analytical Procedures: Methodology. International Conference on Harmonisation; 1996.; Guideline on bioanalytical method validation. EMEA/CHMP/EWP/192217/2009.; ICH Q6B Specifications: Test Procedures and Acceptance Criteria for Biotechnological/Biological Products. International Conference on Harmonisation; 1999.; Guideline on Comparability of Medicinal Products Containing Biotechnology-Derived Proteins as Drug Substance: Non-clinical and Clinical Issues. CPMP/3097/02.; ICH topic Q5E, Step 5 Note for Guidance on Biotechnological/Biological Products Subject to changes in their Manufacturing Process. CHMP/ ICH/5721/03. EMA. June 2005.; Guideline on Comparability of Biotechnology-Derived Medicinal Products after a Change in the Manufacturing Process. Non-Clinical and Clinical Issues. EMEA/CPMP/BMWP/101695/2006. London. 19 July 2007.; https://www.biopreparations.ru/jour/article/view/2; undefined

  7. 7
  8. 8
  9. 9
    Academic Journal
  10. 10
  11. 11
  12. 12
  13. 13
    Academic Journal

    Relation: Кирилюк, Д. И. Параметризация кривых линий на основе апроксимации окружностями / Д. И. Кирилюк, Ю. И. Кулаженко // Телекоммуникации: сети и технологии, алгебраическое кодирование и безопасность данных : материалы международного научно- технического семинара. (Минск, апрель – декабрь 2015 г.). – Минск : БГУИР, 2015. – С. 74 – 76.; https://openrepository.ru/article?id=214327

  14. 14
  15. 15
  16. 16
    Dissertation/ Thesis
  17. 17
    Electronic Resource